Kamada (XTAE:KMDA) Short-Term Debt : ₪0.0 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Kamada Short-Term Debt?

Kamada's Short-Term Debt for the quarter that ended in Mar. 2024 was ₪0.0 Mil.

Kamada's annual Short-Term Debt increased from Dec. 2021 (₪9.7 Mil) to Dec. 2022 (₪16.3 Mil) but then declined from Dec. 2022 (₪16.3 Mil) to Dec. 2023 (₪0.0 Mil).

Kamada Short-Term Debt Historical Data

The historical data trend for Kamada's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Short-Term Debt Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

1.80

0.87

9.66

16.31

Kamada Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															16.31	16.31	-	-	-

Kamada Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Kamada Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Kamada's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (XTAE:KMDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

KMDA:USA

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.